EDGAR·FLOW

Endovia Health Sciences, Inc. — Form 8-K

Filed September 22, 2026 · analyzed by the 8-K Agent
8-K ▲ Likely positive significance 72/100
What the filing says
Endovia Health Sciences closed $500,000 in secured convertible debt from C/M Capital Master Fund, LP on September 22, 2026, the first tranche of a previously announced $1 million commitment. Proceeds support development of CannEpil, a cannabinoid veterinary therapeutic in FDA INAD program for canine cancer pain, and international commercialization. Filing emphasizes favorable regulatory backdrop: FDA launched botanical drug development initiative and Congress introduced H.R. 10150 (Advancing Botanical Drug Development Act) proposing 12-year market exclusivity for approved botanical drugs.
Why this rating

Funding is ~7.7% of $6.5M market cap—material for a micro-cap. Validates strategy, extends runway, and favorable regulatory environment reduces development risk.

Tradability signal
NO TRADE

No trade: price $0.25 is below our $0.5 floor — spreads at this level eat any edge. (Filing arrived outside market hours — evaluated at the next open with a live quote.)

Derived from this site's own measured outcomes + live price/liquidity at analysis time. An experiment, not investment advice.

Price action (we called it positive)
before filing · preread
$0.23 ▲ 1.30%
at our read · unknown
$0.23
+10 min · unknown
$0.27 ▲ 15.35%
+30 min · unknown
$0.28 ▲ 19.43%
+1 hr · unknown
$0.26 ▲ 11.01%
+4 hrs · unknown
$0.19 ▼ 16.31%

The stock had already moved -1.28% between hitting EDGAR and our read finishing — deltas above are measured from our read.

Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →

View original filing on SEC.gov ↗ EDVA · stock on Yahoo Finance ↗

See more from September 22, 2026.

EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.